Israel-based AION Labs, an AI-enabled drug discovery partnership between international pharma and tech corporations, introduced the launch of its second startup, DenovAI.
DenovAI will develop an AI-enabled computational biophysics platform that may uncover potential antibodies directed towards particular epitopes (the a part of an antigen molecule acknowledged by the immune system to which an antibody attaches itself). The corporate mentioned the platform will design antibodies from scratch, then counsel which candidates will probably make efficient medicine.
AION Labs was constructed beneath a authorities tender and contains pharma giants AstraZeneca, Merck, Pfizer and Teva, alongside enterprise capital agency Israel Biotech Fund, strategic companion Amazon Net Companies and German impartial analysis institute Bio Med X.
Funding and pharmaceutical knowledge for machine studying growth and mannequin coaching can be supplied to DenovAI by AION Labs.
“We have now seen main advances within the discipline of therapeutic antibodies, however the means of creating new medicine is extremely sluggish, vastly costly and inefficient. With the assist of AION Labs and its companions, we hope to develop a cutting-edge answer that may disrupt the entire discipline, slicing discovery timelines from months to days. And which may dramatically broaden the scope of antibody remedy to many extra ailments,” Dr. Kashif Sadiq, founder and CEO of DenovAI, mentioned in a press release.
THE LARGER TREND
AION Labs introduced its first startup final yr, dubbed OMEC.AI, which goals to construct an AI-enabled computational platform to assist researchers assess the medical trial readiness of a drug candidate, determine hidden security liabilities and counsel experiments to shut any recognized gaps.
“What we’re attempting to realize at AION Labs on the whole … is creating nice independent-growth AI-based startups for the biotech discipline so we will help scientists and researchers — to not substitute them, however to actually empower them by bringing new technological functionality in order that they’ll optimize the entire means of drug discovery and growth,” Mati Gil, CEO of AION Labs, instructed MobiHealthNews in September.
Different corporations using AI instruments for drug discovery embody drug analysis platform Insilico Medication and UK-based well being tech agency Healx, which makes use of AI to speed up drug discovery and coverings for uncommon ailments.